(Q53302466)

13 May 2018

title

Reduced TNF-α and increased IGF-I levels in the serum of Alzheimer's disease patients treated with the neurotrophic agent cerebrolysin. (English)

1 reference

13 May 2018

0 references

1 reference

3

Ramon Cacabelos

1 reference

13 May 2018

X Anton Alvarez

1

1 reference

13 May 2018

Carolina Sampedro

2

1 reference

13 May 2018

Carlos Linares

4

1 reference

13 May 2018

Manuel Aleixandre

5

1 reference

13 May 2018

Manuel García-Fantini

6

1 reference

13 May 2018

Herbert Moessler

7

1 reference

13 May 2018

publication date

17 June 2009

1 reference

13 May 2018

The International Journal of Neuropsychopharmacology

published in

1 reference

13 May 2018

volume

12

1 reference

13 May 2018

issue

7

1 reference

13 May 2018

page(s)

867-872

1 reference

13 May 2018

Use of serum insulin-like growth factor-I levels to predict psychiatric non-response to donepezil in patients with Alzheimer's disease.

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990101

7 January 2021

Rapid cognitive improvement in Alzheimer's disease following perispinal etanercept administration

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990101

7 January 2021

Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990101

7 January 2021

Down-regulation of DENN/MADD, a TNF receptor binding protein, correlates with neuronal cell death in Alzheimer's disease brain and hippocampal neurons

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990101

7 January 2021

The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990101

7 January 2021

Insulin reduces cerebral ischemia/reperfusion injury in the hippocampus of diabetic rats: a role for glycogen synthase kinase-3beta

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990101

7 January 2021

Trophic factors counteract elevated FGF-2-induced inhibition of adult neurogenesis

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990101

7 January 2021

A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990101

7 January 2021

Serum TNF-alpha levels are increased and correlate negatively with free IGF-I in Alzheimer disease.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990101

7 January 2021

Cerebrolysin decreases amyloid-beta production by regulating amyloid protein precursor maturation in a transgenic model of Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990101

7 January 2021

Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990101

7 January 2021

Plasma cytokine profiles in depressed patients who fail to respond to selective serotonin reuptake inhibitor therapy

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990101

7 January 2021

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990101

7 January 2021

Cerebrolysin ameliorates performance deficits, and neuronal damage in apolipoprotein E-deficient mice.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990101

7 January 2021

The Clinician Interview-Based Impression (CIBI): a clinician's global change rating scale in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990101

7 January 2021

Rescue of TNFalpha-inhibited neuronal cells by IGF-1 involves Akt and c-Jun N-terminal kinases

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990101

7 January 2021

Inflammatory biomarkers are associated with total brain volume: the Framingham Heart Study

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990101

7 January 2021

Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990101

7 January 2021

RETRACTED: A new mechanism of neurodegeneration: a proinflammatory cytokine inhibits receptor signaling by a survival peptide

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990101

7 January 2021

Targeting insulin-like growth factor-1 to treat Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990101

7 January 2021

Inflammatory markers and the risk of Alzheimer disease: the Framingham Study

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990101

7 January 2021

10.1017/S1461145709990101

Identifiers

DOI

1 reference

13 May 2018

1 reference

13 May 2018